A prospective controlled multicentre study of clarithromycin in pregnancy

American Journal of Perinatology

Volumn 15, Issue 9, 1998, Pages 523-525

  Einarson, Adrienne ^a,f   Phillips, Elizabeth ^a   Mawji, Fazaleet ^a   D'Alimonte, Diana ^a   Schick, Betsy ^b   Addis, Antonio ^c   Mastroiacova, Pierpaolo ^d   Mazzone, Teresa ^d   Matsui, D ^e   Koren, Gideon ^a  

^a Motherisk Program   (Canada)

^b Pregnancy Riskline   (United States)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Telefono Rosso   (Italy)

^e FRAME Program   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Biaxin ; Clarithromycin; Humans; Pregnancy

Indexed keywords

CLARITHROMYCIN; MACROLIDE;

ARTICLE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDICATION; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY;

EID: 0032416246     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994053     Document Type: Article

References (8)

1. Product information, Biaxin®, Abbott Laboratories, 1998
2. Skrabanek P. Smoking and statistical overkill. Lancet 1992; 340:1208-1209
3. Compendium of Pharmaceuticals and Specialties: Canadian Pharmaceutical Association, 1998
4. USPDI 1998
5. Briggs Update, volume 9(3), September 1990, FDA (Personal Communication, F. Rosa)
6. Schick B, Hom M, Librizzi R, Donnenfeld A. Pregnancy outcome following exposure to clarithromycin. Reprod Toxicol 1996;10:162
7. Marden PM, Smith DW, McDonald MJ. Congenital anomalies in newborn infants, including minor variations. J Pediatr 1964;64:357-371
8. Goldberg JD, Golbus MS. The value of case reports in human teratology. Am J Obstet Gynecol 1986;154(3):479-482